Relmada Therapeutics, Inc. (RLMD) Financial Statements
Industry: Pharmaceutical Preparations
In fiscal 2025, Relmada Therapeutics reported revenue of $0. Net income was -$57.4M, or -$1.45 per diluted share. Operating activities generated -$45.8M of cash. At fiscal year end, Relmada Therapeutics held $94.0M in total assets against $7.5M in total liabilities, including $3.5M of cash and equivalents.
Open the full interactive Relmada Therapeutics financials → Quarterly statements, key ratios, valuation history and price charts.
Relmada Therapeutics Key Stats
| Share Price | $3.36 |
|---|---|
| Market Cap | $377.6M |
| 52-Week Range | $1.93 – $7.86 |
| Shares Outstanding | 112.4 million (basic, 2026 Q2) |
Relmada Therapeutics Income Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 |
| Operating Income | -$60.8M | -$125.7M | -$161.2M | -$103.7M | -$83.9M | -$59.1M |
| Pre-Tax Income | -$59.5M | -$125.8M | -$157.0M | -$98.8M | -$80.0M | -$57.4M |
| Net Income | -$59.5M | -$125.8M | -$157.0M | -$98.8M | -$80.0M | -$57.4M |
| Diluted EPS | -$3.81 | -$7.16 | -$5.30 | -$3.28 | -$2.65 | -$1.45 |
Relmada Therapeutics Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Net Income | -$10.1M | -$19.9M | -$19.1M | -$12.9M |
| Diluted EPS | -$0.30 | -$0.50 | -$0.22 | -$0.11 |
Relmada Therapeutics Balance Sheet
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $2.5M | — | $5.4M | $4.1M | $3.9M | $3.5M |
| Current Assets | $118.1M | $223.3M | $152.9M | $97.5M | $45.8M | $94.0M |
| Total Assets | $118.2M | $223.3M | $152.9M | $97.6M | $45.8M | $94.0M |
| Current Liabilities | $12.6M | $15.1M | $12.5M | $12.2M | $10.3M | $6.4M |
| Total Liabilities | $12.6M | $15.1M | $12.5M | $12.2M | $10.3M | $7.5M |
| Shareholders' Equity | $105.6M | $208.3M | $140.4M | $85.4M | $35.5M | $86.5M |
Relmada Therapeutics Cash Flow Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash From Operations | -$27.8M | -$91.9M | -$103.8M | -$51.7M | -$51.8M | -$45.8M |
| Cash From Investing | -$34.4M | -$54.1M | $19.7M | $50.5M | $51.6M | -$48.1M |
| Cash From Financing | $28.5M | $187.9M | $45.0M | -$98,463 | -$40,341 | $93.6M |
| Free Cash Flow | -$209.9M | — | — | — | — | — |
Figures from Relmada Therapeutics' 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full Relmada Therapeutics financials page for every line item.
Relmada Therapeutics Company Profile
| Ticker | RLMD |
|---|---|
| Exchange | Nasdaq |
| Industry | Pharmaceutical Preparations |
| Headquarters | Coral Gables, Florida |
| Incorporated in | Nevada |
| Fiscal Year End | December 31 |
| SEC Filer Category | Non-accelerated filer, smaller reporting company |
| SEC CIK | 0001553643 |
Frequently Asked Questions
What was Relmada Therapeutics' revenue in fiscal 2025?
Relmada Therapeutics (RLMD) reported revenue of $0 for fiscal 2025.
What is Relmada Therapeutics' annual revenue history?
Relmada Therapeutics' annual revenue by fiscal year: 2020: $0; 2021: $0; 2022: $0; 2023: $0; 2024: $0; 2025: $0.
What was Relmada Therapeutics' net income in fiscal 2025?
Relmada Therapeutics reported net income of -$57.4M for fiscal 2025.
What was Relmada Therapeutics' earnings per share (EPS) in fiscal 2025?
Relmada Therapeutics' diluted EPS was -$1.45 for fiscal 2025 (adjusted for any later stock splits).
What was Relmada Therapeutics' revenue last quarter?
In its most recent reported quarter (2026 Q2), Relmada Therapeutics reported revenue of $0.
How many shares of Relmada Therapeutics are outstanding?
Relmada Therapeutics reported a weighted average of 112.4 million basic shares outstanding in 2026 Q2.
What is Relmada Therapeutics' market cap?
Based on its latest closing price, Relmada Therapeutics (RLMD) has a market capitalization of about $377.6M.
When does Relmada Therapeutics' fiscal year end?
Relmada Therapeutics' fiscal year end, as registered with the SEC, is December 31.
Where is Relmada Therapeutics headquartered?
Relmada Therapeutics lists its business address in Coral Gables, Florida in its SEC filings.